Skip to main content
Clinical Trials/NCT01113866
NCT01113866
Completed
Not Applicable

Circulating Biomarkers as Prognostic Indicators of Death in Ambulatory Heart Failure Patients

University of Parma1 site in 1 country124 target enrollmentOctober 1998
ConditionsHeart Failure

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Heart Failure
Sponsor
University of Parma
Enrollment
124
Locations
1
Status
Completed
Last Updated
16 years ago

Overview

Brief Summary

Biomarkers representing distinct biological domains including neurohormonal, inflammatory, metabolic-nutritional, oxidative-nitrosative and myocardial injury, might alone or in combination provide prognostic information on mortality in heart failure patients with preserved or impaired systolic function.

Detailed Description

Upon enrollment in the study, Troponin I (cTn I), BNP, norepinephrine, plasma renin activity, aldosterone, high-sensitivity C-reactive protein (hs-CRP), tumor necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6), soluble receptor of interleukin 2 (sIL-2R), leptin, prealbumin, free malondialdehyde, 15-F2t-isoprostane and protein-bound nitrotyrosine were measured in stable ambulatory, non diabetic, elderly heart failure patients. Patients were followed up until death or study termination (31st January 2009).

Registry
clinicaltrials.gov
Start Date
October 1998
End Date
January 2009
Last Updated
16 years ago
Study Type
Observational
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • symptomatic congestive heart failure lasting at least six months
  • reduced exercise tolerance
  • impaired or preserved left ventricular ejection fraction
  • cardiomegaly

Exclusion Criteria

  • acute infection
  • rheumatoid or other autoimmune diseases
  • primary cachectic states (cancer, thyroid disease, severe liver disease)
  • severe chronic lung disease
  • neuromuscular disorders
  • myocardial infarction within the previous 20 weeks
  • diabetes mellitus
  • chronic renal failure (serum creatinine level \> 2.0 mg/dl, \>177 micromol/L)

Outcomes

Primary Outcomes

Not specified

Study Sites (1)

Loading locations...

Similar Trials